Upstream Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Upstream Bio (Nasdaq: UPB) will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 at 2:15 p.m. PT. Rand Sutherland, MD, Chief Executive Officer, will deliver the presentation. A live webcast will be available under the Events tab on the Investors section of Upstream Bio’s website on the day of the event, and a replay will be posted on the company website after the presentation.
Positive
- None.
Negative
- None.
News Market Reaction – UPB
On the day this news was published, UPB declined 3.47%, reflecting a moderate negative market reaction. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $49M from the company's valuation, bringing the market cap to $1.37B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Key biotech peers show mixed to negative moves: SYRE -6.65%, RAPP -6.46%, QURE -2.66%, while TRML is flat and VERV is marginally lower (-0.09%). No coordinated sector momentum appears around this conference update.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 25 | Investor conferences | Neutral | +10.7% | Announcement of CEO participation in two December 2025 investor conferences. |
| Nov 05 | Earnings & pipeline | Positive | -4.3% | Q3 2025 results with positive Phase 2 CRSwNP data and solid cash runway. |
| Oct 31 | Investor events | Neutral | +0.3% | Planned CEO participation in three November 2025 healthcare investor events. |
| Sep 30 | Clinical data | Positive | +8.5% | Presentation of structural and mechanistic data supporting verekitug’s differentiated profile. |
| Sep 09 | Single conference | Neutral | -2.6% | Announcement of CEO fireside chat at Stifel 2025 Virtual Immunology Forum. |
Recent history shows mixed reactions: positive clinical and earnings updates sometimes saw negative moves, while neutral conference participation occasionally coincided with notable gains.
Over the past few months, Upstream Bio has combined clinical progress with active investor outreach. Positive Phase 2 data for verekitug and mechanistic findings in respiratory disease were reported in early September 2025, followed by continued conference participation in September, October, and November 2025. Q3 2025 results on November 5, 2025 highlighted cash runway through 2027 and advancing Phase 2 programs. Today’s J.P. Morgan Healthcare Conference appearance extends this pattern of regular investor and scientific visibility rather than representing a new clinical data event.
Market Pulse Summary
This announcement highlights Upstream Bio’s upcoming presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 at 2:15 p.m. PT, extending a pattern of regular conference engagement. Webcast and replay access underscore an emphasis on investor communication. In the months leading up to this, the company reported Phase 2 data and maintained a cash runway discussed in recent filings. Investors may watch for future trial readouts and financial updates to assess longer-term implications.
AI-generated analysis. Not financial advice.
WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will be presenting at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 2:15 p.m. PT.
A live webcast of the presentation will be available under the Events tab on the Investors section of Upstream Bio’s website on the day of the event. A replay will be available on the Company's website following the presentation.
About Upstream Bio
Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. Upstream Bio is developing verekitug, the only known antagonist currently in clinical development that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. Upstream Bio has advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma and chronic obstructive pulmonary disease (COPD). Upstream Bio’s team is committed to maximizing verekitug’s unique attributes to address the substantial unmet needs for patients underserved by today’s standard of care. To learn more, please visit www.upstreambio.com.
Investor and Media Contact:
Meggan Buckwell
Director, Corporate Communications and Investor Relations
ir@upstreambio.com
FAQ
When will Upstream Bio (UPB) present at the J.P. Morgan Healthcare Conference?
Who will present for Upstream Bio (UPB) at the January 12, 2026 conference?
How can investors watch Upstream Bio's (UPB) J.P. Morgan presentation on January 12, 2026?
Will there be a replay of Upstream Bio's (UPB) January 12, 2026 presentation?
What topics will Upstream Bio (UPB) likely cover at the January 12, 2026 presentation?
